Head-to-Head: which drug better opens swallowing tubes?
NCT ID NCT07358234
Summary
This study aims to find out if a newer injectable drug (dupilumab) works better than a swallowed steroid liquid (budesonide) at widening the esophagus and reducing scar tissue in adults with eosinophilic esophagitis (EoE). Researchers will measure changes in the esophagus after 12 weeks of treatment in 60 participants. The goal is to see which treatment more effectively controls the disease and prevents long-term complications like narrowing of the food pipe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS (EOE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.